A single dose of psilocybin therapy increased global brain integration in people with depression, with effects lasting for weeks. The brain's regions communicated more broadly and flexibly after treatment, a pattern linked to reduced depressive symptoms. This neural change suggests psilocybin may help reorganize brain networks that become rigid in depression.
The text is a brief, playful title that reinterprets the abbreviation MDMA, suggesting a connection to medical doctors (MD) rather than providing substantive content. It does not present a finding, argument, or data.
A single 21.5-mg intravenous dose of the psychedelic DMT, given with psychotherapeutic support, produced a rapid and significant reduction in depressive symptoms in adults with moderate-to-severe major depressive disorder. In a double-blind, placebo-controlled trial with 34 participants, those receiving DMT showed a greater decrease in depression scores at two weeks compared to placebo. Antidepressant effects persisted up to three months in an open-label phase. Adverse events were mostly mild to moderate, and no serious adverse events occurred.